KALA vs NVCR vs BEAM vs FATE

For growth investors, Beam Therapeutics Inc.

(BEAM) is the stronger pick with 120. 0% revenue growth year-over-year, versus -51. 2% for Fate Therapeutics, Inc. (FATE). Analysts rate KALA BIO, Inc. (KALA) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Beam Therapeutics Inc.

(BEAM) delivered a total return of -55. 6%, compared to -100. 0% for KALA BIO, Inc. (KALA). Over 10 years, the gap is even starker: BEAM returned +67. 8% versus KALA's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), KALA BIO, Inc.

(KALA) is the lower-risk stock at 2. 09β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 5% more volatile than KALA relative to the S&P 500. On balance sheet safety, Beam Therapeutics Inc. (BEAM) carries a lower debt/equity ratio of 24% versus 3% for KALA BIO, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Beam Therapeutics Inc.

(BEAM) is pulling ahead at 120. 0% versus -51. 2% for Fate Therapeutics, Inc. (FATE). On earnings-per-share growth, the picture is similar: Beam Therapeutics Inc. grew EPS 82. 3% year-over-year, compared to 21. 8% for NovoCure Limited. Over a 3-year CAGR, BEAM leads at 31. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

NovoCure Limited (NVCR) is the more profitable company, earning -20.

8% net margin versus -141. 1% for KALA BIO, Inc. — meaning it keeps -20. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVCR leads at -23. 5% versus -150. 6% for KALA. At the gross margin level — before operating expenses — BEAM leads at 84. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Beam Therapeutics Inc.

(BEAM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. KALA BIO, Inc. (KALA) carries a higher beta of 2. 09 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BEAM: +67. 8%, KALA: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: KALA is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; BEAM is a small-cap high-growth stock; FATE is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.